RhumbLine Advisers’s Albireo Pharma Inc ALBO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-22,452
| Closed | -$485K | – | 2981 |
|
|
2022
Q4 | $485K | Buy |
22,452
+1,155
| +5% | +$24.4K | ﹤0.01% | 2478 |
|
|
2022
Q3 | $412K | Buy |
21,297
+1,424
| +7% | +$29.4K | ﹤0.01% | 2585 |
|
|
2022
Q2 | $395K | Buy |
19,873
+1,903
| +11% | +$50.2K | ﹤0.01% | 2614 |
|
|
2022
Q1 | $536K | Buy |
17,970
+216
| +1% | +$6.32K | ﹤0.01% | 2397 |
|
|
2021
Q4 | $413K | Sell |
17,754
-306
| -2% | -$8.14K | ﹤0.01% | 2584 |
|
|
2021
Q3 | $563K | Buy |
18,060
+601
| +3% | +$18.6K | ﹤0.01% | 2491 |
|
|
2021
Q2 | $614K | Sell |
17,459
-1,307
| -7% | -$42.5K | ﹤0.01% | 2469 |
|
|
2021
Q1 | $662K | Sell |
18,766
-970
| -5% | -$35.8K | ﹤0.01% | 2363 |
|
|
2020
Q4 | $740K | Buy |
19,736
+3,757
| +24% | +$137K | ﹤0.01% | 2270 |
|
|
2020
Q3 | $533K | Sell |
15,979
-1,263
| -7% | -$36.8K | ﹤0.01% | 2264 |
|
|
2020
Q2 | $457K | Buy |
17,242
+3,445
| +25% | +$81.3K | ﹤0.01% | 2391 |
|
|
2020
Q1 | $226K | Buy |
13,797
+555
| +4% | +$12.2K | ﹤0.01% | 2533 |
|
|
2019
Q4 | $337K | Buy |
13,242
+92
| +0.7% | +$1.84K | ﹤0.01% | 2537 |
|
|
2019
Q3 | $263K | Buy |
13,150
+100
| +0.8% | +$2.59K | ﹤0.01% | 2631 |
|
|
2019
Q2 | $421K | Buy |
13,050
+144
| +1% | +$4.82K | ﹤0.01% | 2433 |
|
|
2019
Q1 | $416K | Sell |
12,906
-150
| -1% | -$4.04K | ﹤0.01% | 2404 |
|
|
2018
Q4 | $320K | Buy |
13,056
+3,743
| +40% | +$98.9K | ﹤0.01% | 2511 |
|
|
2018
Q3 | $307K | Sell |
9,313
-125
| -1% | -$4.09K | ﹤0.01% | 2508 |
|
|
2018
Q2 | $335K | Buy |
+9,438
| New | +$306K | ﹤0.01% | 2477 |
|
Other funds holding ALBO
RhumbLine Advisers's ALBO Position: Q1 2023 in Review
RhumbLine Advisers sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 22,452 shares — an estimated $485K sold.
RhumbLine Advisers first reported a position in ALBO in Q2 2018 and held it in 19 quarters. The position peaked at $740K in Q4 2020. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.
- RhumbLine Advisers reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
- RhumbLine Advisers sold 22,452 Albireo Pharma Inc shares in Q1 2023, an estimated $485K.
- RhumbLine Advisers first reported a position in Albireo Pharma Inc in Q2 2018 and held it in 19 quarters.
- RhumbLine Advisers's Albireo Pharma Inc position peaked at $740K in Q4 2020.
- 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.
Based on RhumbLine Advisers's 13F filing for Q1 2023, filed 11 May 2023.